Search results
Results from the WOW.Com Content Network
(Reuters) - Johnson & Johnson plans to split into two companies, separating its consumer health division that sells Band-Aids and Baby Powder from its pharmaceuticals and medical devices business ...
Johnson & Johnson has wasted no time expanding its portfolio. In the past two years it has invested more than $60 billion into research and development (R&D), as well as mergers and acquisitions ...
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
By Steven Brill Letter From the Editors Backstage at Johnson & Johnson. On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more than a billion dollars in annual sales.
Johnson & Johnson has a global workforce of approximately 130,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato. Johnson & Johnson was founded in 1886 by three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, selling ready
LifeScan was established in 1981. [3] It was acquired by Johnson & Johnson (J&J) in 1986, [2] [4] and in June 2018, J&J agreed to sell LifeScan to Platinum Equity as part of its strategic exit from the diabetes device market, accepting an offer originally tendered in March 2018. [1]
The first step began in October 2021 when Johnson & Johnson’s parent company formed the subsidiary LTL Management, transferring its existing 38,000 talc claims to LTL.
The Motley Fool 20 minutes ago Is It Finally Time to Give Up on UPS After the High-Yield Dividend Stock Crashed to a 4-Year Low? United Parcel Service (NYSE: UPS) stock fell 14.1% on Jan. 30 after the company reported disappointing fourth-quarter and full-year 2024 results.